That explains a lot.
" These lesions then shrink over time most likely due to scarring, and in humans, these lesions reach a plateau around 6 months after the RF91 and 3 months after the MRIgFUS interventions.65 92 93"
jnnp.bmj.com/content/89/7/7...
researchgate.net/publicatio...
(You can find a blow up of this graph in the link.)
I wonder if the lesion shrinkage is due to the dead cells that got zapped being cleared out. Their function would not necessarily have been replaced.
I am looking for the explanation
Mark, could you explain for those of us who have some trouble understanding the clinical trial documents, what is important about this information?
It might explain why if (or that) some symptoms might partially return after the FUS surgery.
I knew this based on my experience. Or, at least. I am convinced this is what happened to me.
Where and when did you have FUS?
2016 in Baltimore as part of the research study for FUS pallidotomy. I’ve posted about it in the past.
How satisfied are you with it?
Not very as it did not last very long (4-6 months). My theory is that initially the lesion was bigger and there was swelling that gave me a better result, but as the lesion shrunk and the swelling went down the benefits were lost.
I am sorry to hear that.
MRIgFUS works! But...
Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy 2021
The Epidemiology of Parkinson's Disease
MRigFUS in Switzerland - 9 months update
Reductions in fecal short-chain fatty acids (SCFAs) but increased plasma SCFAs were observed in patients with Parkinson's disease
